CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence

概要

Side population (SP) is known to include therapy-resistant cells in various cancers. Here, we analyzed SP using multiple myeloma (MM) samples. The SP accounted for 2.96% in MM cells from newly diagnosed MM (NDMM). CD34 was expressed in 47.8% of SP cells, but only in 2.11% of bulk MM cells. CD34+ MM cells expressed more immature cell surface markers and a gene signature than CD34- MM cells. CD34+ but not CD34- MM cells possessed clonogenic activities and showed long-term self- renewal activities in xenotransplantation assays. Similarly, whereas 2.20% of MM cells were CD34+ in NDMM (n=38), this proportion increased to 42.6% in minimal residual disease (MRD) samples (n=16) (p<0.001) and to 17.7% in refractory/relapsed MM (RRMM) (n=30) (p<0.01). Cell cycle analysis showed that 24.7% of CD34+ MM cells from NDMM were in G0 phase while this proportion was 54.9% in MRD (p＜0.05) and 14.5% in RRMM, reflecting the expansion of MM. Together, CD34+ MM cells with long- term self-renewal activities persist as MRD in cell cycle quiescence or remain as therapy-resistant cells in RRMM, substantiating the necessity of targeting this population to improve clinical outcomes of MM.